Opinion

Video

Treatment Options in Atopic Dermatitis

Panelists discuss how recent treatment approvals for atopic dermatitis (AD), including new biologics and systemic therapies, are reshaping management, and emphasize how patient factors, such as severity, comorbidities, and treatment history, guide treatment selection in AD.

Video content above is prompted by the following:

  • Please review new treatments that have been approved in recent years for AD.
  • With many effective treatments available for AD, what factors guide your treatment selection?
Related Videos
3 experts are featured in this series.
John Kane, MD | Credit: Northwell Health
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Related Content
Credit: Adobe Stock/ Pixel-Shot
January 14th 2025

Poor Sleep Quality Linked to Greater Blood Pressure in Adults with Optimal Sleep Duration

Chelsie Derman
Diabetes Dialogue: The Role of Dietitians in GLP-1 RA Use | Image Credit: HCPLive
January 13th 2025

Diabetes Dialogue: The Evolving Role of Registered Dietitian Nutritionists in Obesity

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Baricitinib Effective, Safe Over 52 Weeks for Severe Alopecia Areata
January 13th 2025

Baricitinib Effective, Safe Over 52 Weeks for Severe Alopecia Areata

Tim Smith
Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas | Image Credit: HCPLive
January 6th 2025

Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Kidney disease | Credit: Fotolia
January 13th 2025

Revised Hyperfiltration Formula Incorporates Age-Related Renal Function Decline

Abigail Brooks, MA
OCU400 Improves 2-Year Vision in Retinitis Pigmentosa in Phase 1/2 Trial | Image Credit: Gundersen Health System
January 13th 2025

OCU400 Improves 2-Year Vision in Retinitis Pigmentosa in Phase 1/2 Trial

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.